Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Multiple Sclerosis Journal Année : 2022

Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis

Résumé

Meeting Abstract EP1163 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis Amsterdam, NETHERLANDS OCT 26-28, 2022
Fichier non déposé

Dates et versions

hal-03922630 , version 1 (04-01-2023)

Identifiants

  • HAL Id : hal-03922630 , version 1

Citer

M Chappuis, C. Rousseau, E. Bajeux, G. Edan, Laure Michel, et al.. Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28 (3_SUPPL), pp.911-912. ⟨hal-03922630⟩
6 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More